EUVIMEDEUVIMED entdecken
Crossref

Prognosis of patients with wild‐type transthyretin cardiac amyloidosis and non‐sustained ventricular tachycardia

Ojasav Sehrawat iD, William H Swain, Hannah P Alcantara, Nicholas Y Tan iD, Omar F Abou Ezzeddine, Martha Grogan, Angela Dispenzieri, Grace Lin, Peter A Noseworthy iD, Konstantinos C Siontis iD

Journal of Cardiovascular Electrophysiology · 2025-01 · 36 (1) · 124-134

DOI: 10.1111/jce.16470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 06.11.2024. Verfasst von Ojasav Sehrawat und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Tachycardia, Ventricular, Amyloid Neuropathies, Familial, Cardiomyopathies, Heart Rate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Little is known regarding the prevalence and prognostic implications of non‐sustained ventricular tachycardia (NSVT) in patients with wild‐type transthyretin cardiac amyloidosis (ATTRwt‐CA). We aimed to investigate the prevalence of NSVT in patients with ATTRwr‐CA, and the association of NSVT with sustained ventricular arrhythmias (VA) and all‐cause mortality.

Methods

In a cohort of ATTRwt‐CA patients from 2011 to 2022 without prior sustained VA, we ascertained the presence and characteristics of NSVT during clinically indicated ambulatory Holter monitoring. Patients were stratified based on the presence of NSVT at baseline. The primary and secondary endpoints of sustained VA and all‐cause mortality, respectively, were assessed during follow‐up.

Results

The cohort included 217 patients with ATTRwt‐CA (95% males, median age 75 years; median NYHA class 2). Baseline Holter monitoring demonstrated NSVT in 116 (53%) patients. During a median follow‐up of 27 months (IQR 16–45) after the index Holter monitor, 11 (5.1%) patients reached the primary endpoint of sustained VA (incidence 1.8 per 100 person‐years, all monomorphic VT), and 46 (21%) patients died. In univariable Cox proportional hazard model, NYHA class 3 or 4 heart failure ( p = .048), the presence of NSVT ( p = .04), the duration of longest NSVT run ( p = .029), and the percentage of ventricular ectopy ( p < .001) were associated with the primary outcome. When adjusting for age and NYHA class 3 or 4 heart failure, the presence of NSVT remained associated with the primary outcome ( p = .03). All‐cause mortality was not significantly different between patients with and without NSVT. A cutoff for ventricular ectopy burden of 0.5%, the median for all patients in this study, was associated with increased risk in sustained VA (log‐rank p = .004) and mortality (log‐rank p = .02).

Conclusion

NSVT is highly prevalent among ATTRwt‐CA patients undergoing clinically indicated Holter monitoring and may confer an increased risk of incident sustained VA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tachycardia, VentricularAmyloid Neuropathies, FamilialCardiomyopathiesHeart RateHumansMaleFemaleAgedElectrocardiography, AmbulatoryTime FactorsRisk AssessmentRisk FactorsPrevalenceAged, 80 and overPrognosisAction PotentialsRetrospective StudiesMiddle AgedIncidence

Stichwörter der Autor:innen

Holter monitorcardiac amyloidosisnon‐sustained ventricular tachycardiaventricular arrhythmiaventricular ectopywild type transthyretin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Nursing, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Ojasav Sehrawat, Nicholas Y Tan, Peter A Noseworthy, Konstantinos C Siontis

Zitieren

APA

Sehrawat, O., Swain, W. H., Alcantara, H. P., Tan, N. Y., Abou Ezzeddine, O. F., Grogan, M., Dispenzieri, A., Lin, G., Noseworthy, P. A., & Siontis, K. C. (2025). Prognosis of patients with wild‐type transthyretin cardiac amyloidosis and non‐sustained ventricular tachycardia. Journal of Cardiovascular Electrophysiology, 36(1), 124-134. https://doi.org/10.1111/jce.16470

Vancouver

Sehrawat O, Swain WH, Alcantara HP, Tan NY, Abou Ezzeddine OF, Grogan M, et al. Prognosis of patients with wild‐type transthyretin cardiac amyloidosis and non‐sustained ventricular tachycardia. Journal of Cardiovascular Electrophysiology. 2025;36(1):124-134. doi:10.1111/jce.16470

BibTeX
@article{Sehrawat2025,
  author = {Sehrawat, Ojasav and Swain, William H and Alcantara, Hannah P and Tan, Nicholas Y and Abou Ezzeddine, Omar F and Grogan, Martha and Dispenzieri, Angela and Lin, Grace and Noseworthy, Peter A and Siontis, Konstantinos C},
  title = {Prognosis of patients with wild‐type transthyretin cardiac amyloidosis and non‐sustained ventricular tachycardia},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  volume = {36},
  number = {1},
  pages = {124--134},
  doi = {10.1111/jce.16470}
}
Kostenlos starten →